The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and over with inadequately controlled chronic rhinosinusitis with nasal polyps...

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients...

The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic rhinosinusitis with nasal polyps...